MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting ...

In biotechnology, designing gene delivery vectors is a data-intensive process. Every component, from the genetic cargo to the delivery mechanism, is selected based on extensive analysis ...

MAIA Biotechnology, Inc.,, a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that a late-breaking abstract detailing new updates from its ...

NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win ...

MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics. Oct. 15, 2024 8:15 AM ET MAIA Biotechnology, Inc. (MAIA) ...

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines ...

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting Provided by Business Wire May 15, 2025, 3:05:00 PM ...

Nov. 05, 2024 9:45 AM ET MAIA Biotechnology, Inc. (MAIA) 1 Comment Late breaking abstract to provide new updates from THIO-101 Phase 2 clinical trial in non-small cell lung cancer (NSCLC) ...

MAIA Biotechnology, Inc.,, a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract about its Phase 2 THIO-101 clinical trial ...

CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today ...